Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EZYCA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
JP7623413B2 ExampleADC2
|
|||||
| Synonyms |
JP7623413B2 ExampleADC2
Click to Show/Hide
|
|||||
| Organization |
Sumitomo Pharma Co. Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Brentuximab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.02 nM | Positive CD30 expression (CD30+++/++) | ||
| Method Description |
Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 10%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
|
||||
| In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||